Becton, Dickinson and Company (NYSE:BDX) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC lessened its position in Becton, Dickinson and Company (NYSE:BDX) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,257 shares of the medical instruments supplier’s stock after selling 145 shares during the period. TD Private Client Wealth LLC’s holdings in Becton, Dickinson and Company were worth $1,026,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. WR Wealth Planners LLC grew its stake in shares of Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after purchasing an additional 42 shares in the last quarter. Clear Creek Financial Management LLC grew its position in Becton, Dickinson and Company by 5.1% in the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares in the last quarter. Sound Income Strategies LLC increased its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Central Pacific Bank Trust Division raised its position in shares of Becton, Dickinson and Company by 22.5% during the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 45 shares in the last quarter. Finally, Tompkins Financial Corp lifted its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

BDX has been the topic of a number of research analyst reports. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $283.50.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. The trade was a 15.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.7 %

Shares of NYSE:BDX opened at $225.49 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The stock has a market capitalization of $65.19 billion, a price-to-earnings ratio of 37.96, a PEG ratio of 1.64 and a beta of 0.41. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The company has a 50 day moving average price of $231.00 and a 200 day moving average price of $233.34.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same period last year, the company posted $3.42 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.84%. The ex-dividend date of this dividend is Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s payout ratio is presently 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.